课题基金 / 基金详情

Productive role of fractalkine and CXCL16 in human epidermal keratinocytes

Productive role of fractalkine and CXCL16 in human epidermal keratinocytes
fractalkine 和 CXCL16 在人表皮角质形成细胞中的生产作用
批准号:
16591103
负责人:
TOHYAMA Mikiko
金额:
$2.3万
依托单位:
依托单位国家:
日本
项目类别:
Grant-in-Aid for Scientific Research (C)
财政年份:
2004
资助国家:
日本
项目状态:
已结题
起止时间:
2004 至 2005

项目摘要

项目成果

TOHYAMA Mikiko的其他基金

相似基金

相关文献

中文摘要
翻译
CXCL16是一种CXC趋化因子受体CXCR6的配体。CXCL16是以膜结合形式合成的,被切割成可溶性形式,对表达CXCR6的细胞,如活化的CD8T细胞、NKT细胞以及Th1极化的CD4和CD8T细胞具有趋化作用。相比之下,表达在人巨噬细胞和树突状细胞上的一种膜结合形式的CXCL16作为氧化型低密度脂蛋白的清道夫受体。此外,表达在巨噬细胞上的CXCL16还介导了大肠杆菌或金黄色葡萄球菌等细菌的黏附和吞噬。CXCL16的可溶性趋化素结构域在浓度为5-g/ml时对金黄色葡萄球菌和大肠杆菌具有抗菌活性。加入10-g/ml的可溶性CXCL16可使金黄色葡萄球菌和大肠杆菌的存活率分别降低70%和40%。由于CXCL16是由HEK组成性地产生的,因此CXCL16在人体皮肤中参与了与微生物病原体相关的宿主防御功能以及防御。趋化因子Fractalkine/CX3CL1是以膜结合的形式合成的,并被蛋白酶转化为可溶性形式(S)。由于Fractalkine招募CX3CR1阳性细胞,如NK细胞和CD8+T细胞,它被认为参与了炎症反应中将这些细胞招募到表皮中。为了解决这个问题,我们调查了正常人角质形成细胞是否能在细胞因子存在的情况下产生分裂因子。肿瘤坏死因子、白介素1和干扰素协同促进干扰素诱导的正常人角质形成细胞产生Fractalkine。总之,这是第一个表明正常人角质形成细胞产生可溶性Fractalkine蛋白的报告。
英文摘要
CXCL16 is a ligand for CXCR6, a CXC-chemokine receptor. CXCL16 is synthesized as a membrane-bound form that is cleaved to a soluble form that is a chemoattractant for CXCR6-expressing cells such as activated CD8 T cells, NKT cells, and Th1-polarized CD4 and CD8 T cells. By contrast, a membrane-bound form of CXCL16 expressed on human macrophages and dendritic cells acts as a scavenger receptor for oxidized low density lipoprotein. In addition, CXCL16 expressed on macrophages mediates adhesion and phagocytosis of bacteria such as Escheria coli or Staphylococcus aureus. The soluble chemokine domain of CXCL16 at concentrations > 5 □g/ml had antimicrobial activity against S.aureus and E.coli. Addition of 10 □g/ml soluble CXCL16 reduced the survival rate of S.aureus and E.coli by 70 and 40%, respectively. Because CXCL16 is produced constitutively by HEK, CXCL16 contributes to host-defense function in relation to microbial pathogens in human skin as well as □-defensins.Fractalkine/CX3CL1, a chemokine, is synthesized as a membrane bound form and converted to a soluble form by protease(s). Since fractalkine recruits CX3CR1 positive cells such as NK cells and CD8+ T cells, it is supposed to be involved in recruiting these cells into the epidermis in the inflammatory reaction. To address this issue, we investigated whether normal human keratinocytes can produce fractalkine in the presence of cytokines. TNF-□, IL1-□□ and IFN-□ synergistically enhanced IFN-□-induced fractalkine production in normal human keratinocytes. In conclusion, this is the first report showing that normal human keratinocytes produce soluble fractalkine protein.
期刊论文(48)
专著(0)
科研奖励(0)
会议论文
DOI: 10.1016/j.jdermsci.2005.12.011
发表时间: 2006-05
期刊: Journal of dermatological science
影响因子: 4.6
作者: [Lujun Yang;K. Yamasaki;Y. Shirakata;X. Dai;S. Tokumaru;Y. Yahata;M. Tohyama;Y. Hanakawa;K. Sayama;K. Hashimoto]
通讯作者: Lujun Yang;K. Yamasaki;Y. Shirakata;X. Dai;S. Tokumaru;Y. Yahata;M. Tohyama;Y. Hanakawa;K. Sayama;K. Hashimoto
DOI: 10.1038/sj.jid.5700294
发表时间: 2006-07-01
期刊: JOURNAL OF INVESTIGATIVE DERMATOLOGY
影响因子: 6.5
作者: [Dai, Xiuju, Sayama, Koji, Hashimoto, Koji]
通讯作者: Hashimoto, Koji
DOI: 10.1016/j.bbrc.2004.11.145
发表时间: 2005-02-04
期刊: BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS
影响因子: 3.1
作者: [Tokumaru, S, Sayama, K, Hashimoto, K]
通讯作者: Hashimoto, K
TGF-beta is not involved in early phase growth inhibition of keratinocytes by lalpha, 25(OH)2vitamin D3
TGF-β 不参与 lalpha、25(OH)2 维生素 D3 对角质形成细胞的早期生长抑制
DOI: --
发表时间: 2004
期刊: J Dermatol Sci 36
影响因子: --
作者: [Shirakawa Y, Ueno H, Hanakawa Y, et al.]
通讯作者: et al.
共 12 条
    Development of living skin equivalent models over-expressing IL-22R on epidermal keratinocytes
    • 批准号:
      22591241
    • 项目类别:
      Grant-in-Aid for Scientific Research (C)
    • 资助金额:
      $2.83万
    • 财政年份:
      2010
    • 负责人:
      TOHYAMA Mikiko
    • 依托单位:
    国内基金
    海外基金
    Fractalkine通过靶向调节小胶质细胞CD163/SHH表达促进脑出血后血肿吸收和神经血管修复的研究
    • 批准号:
      82071335
    • 项目类别:
      面上项目
    • 资助金额:
      55.0万元
    • 批准年份:
      2020
    • 负责人:
      贺权威
    • 依托单位:
    mTOR调节巨噬细胞极化在Fractalkine介导的慢性间歇低氧所致肝损伤中的作用及分子机制
    • 批准号:
      2020JJ4812
    • 项目类别:
      省市级项目
    • 资助金额:
      --
    • 批准年份:
      2020
    • 负责人:
      王轶娜
    • 依托单位:
    Fractalkine/CX3CR1轴介导羊膜腔注射的骨髓间充质干细胞向胎鼠显性脊柱裂靶向迁移促进神经功能修复的研究
    • 批准号:
      82001643
    • 项目类别:
      青年科学基金项目
    • 资助金额:
      24.0万元
    • 批准年份:
      2020
    • 负责人:
      马巍
    • 依托单位:
    结核分枝杆菌Hsp16.3通过Fractalkine/CX3CR1信号轴调控巨噬细胞M2型极化的作用机制
    • 批准号:
      81860291
    • 项目类别:
      地区科学基金项目
    • 资助金额:
      35.0万元
    • 批准年份:
      2018
    • 负责人:
      罗军敏
    • 依托单位: